PROMOTIONAL FEATURE
Approximately 8 per cent of babies are born before 37 weeks’ gestation in the UK. Preterm birth is a significant cause of perinatal mortality and morbidity and the Department of Health is keen to reduce the UK preterm birth rate to 6 per cent by 2025. [1]
The mechanisms leading to late miscarriage, or spontaneous preterm birth, are multifactorial and only partially understood. While there are some known causes and risk factors, many women who do deliver preterm do not have identifiable risk factors. Meanwhile, many women with known risk factors do not deliver preterm, meaning that clinical decision making around preterm birth is challenging and confusing.
Symptomatic women
Most women presenting with symptoms of threatened preterm labour will not deliver in seven days, and more than 70 per cent of women will eventually deliver at term. [2,3,4] However, many women with symptoms of threatened preterm labour are admitted or transferred to another unit unnecessarily and given unnecessary interventions. I have cared for many women who are devastated at the thought of being transferred and admitted to another unit far away – especially if they have additional children to care for or other commitments. Overtreatment can lead to considerable risks to the mother and fetus, increased stress and anxiety for the woman and her family, and substantial financial costs to the NHS. Predictive testing can help to triage symptomatic women more effectively which can decrease inappropriate management and ward inefficiencies.
Asymptomatic women
Predictive testing can also be undertaken on asymptomatic high-risk women (i.e. women who currently have no symptoms of preterm labour but have a risk factor associated with preterm birth).
My colleagues and I find predictive testing useful from a clinical perspective as it can be used to help guide the antenatal appointment care plan for a woman, and determine which women require potential interventions (e.g. a cervical cerclage).
Predictive tests available
The current predictive tests available include transvaginal ultrasound measurement of the cervical length and biomarker swab tests. In the UK there are three biomarker swab tests available: Fetal Fibronectin (fFN), Actim® Partus and PartoSure™.
Current preterm birth guidance recommends that if a transvaginal cervical length scan is indicated but is not available or not acceptable, an fFN test could be undertaken to help diagnose preterm labour when a woman presents with symptoms of threatened preterm labour and intact membranes. [5] Where I have worked clinically in Central London, transvaginal ultrasound is often not available due to limited equipment and expertise – something which is common to lots of hospital units. [6] Meanwhile, an fFN test can be undertaken by anyone who is competent using a vaginal speculum. NICE has concluded that more research is required on the other two biomarker tests (Actim® Partus and PartoSure™). [6]
fFN testi
